Lawsuit filed for Investors in shares of Elanco Animal Health Incorporated (NYSE: ELAN)

An investor, who purchased shares of Elanco Animal Health Incorporated (NYSE: ELAN), filed a lawsuit over alleged violations of Federal Securities Laws by Elanco Animal Health Incorporated in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Elanco Animal Health Incorporated (NYSE: ELAN) have certain options and for certain investors are short and strict deadlines running. Deadline: December 6, 2024. NYSE: ELAN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Greenfield, IN based Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. The Company is developing Zenrelia, a "safe, highly effective, and convenient" once-daily oral Janus kinase inhibitor for canine dermatology, and Credelio Quattro, a broad spectrum parasiticide product for dogs.
In November 2023, Elanco Animal Health Incorporated set a timeline for the (United States) ("U.S.") approval of both Zenrelia and Credelio Quattro in the first half of 2024.

Elanco Animal Health Incorporated reported that its annual Total Revenue rose from $4.411 billion in 2022 to $4.417 billion in 2023, and that its Net Loss increased from $78 million in 2022 to over $1.23 billion in 2023.

On June 27, 2024 Elanco Animal Health Incorporated announced "updates to the expected U.S. Food and Drug Administration (FDA) approval timelines for Zenrelia and Credelio Quattro." The press release stated that Zenrelia is expected to receive FDA approval in the third quarter of 2024, leading to a potential commercial launch in the fourth quarter of 2024. The Company had previously set a launch timeline for the third quarter of 2024. The press release also stated that Credelio Quattro is expected to receive FDA approval in the fourth quarter of 2024, while the Company had previously set an approval timeline for the third quarter of 2024.

Shares of Elanco Animal Health Incorporated (NYSE: ELAN) declined from $18.65 per share on June 5, 2024, to $12.57 per share on July 19, 2024.

The plaintiff claims that between November 7, 2023 and June 26, 2024, the Defendants made false and/or misleading statements and/or failed to disclose that Zenrelia was less safe than the Company had led investors to believe, that Elanco was unlikely to meet its own previously issued timeline for the U.S. approval and commercial launch of both Zenrelia and Credelio Quattro, that accordingly, the Company's business and/or financial prospects were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Elanco Animal Health Incorporated (NYSE: ELAN) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.